{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:42:24Z","timestamp":1777603344908,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["5K12EY016335"],"award-info":[{"award-number":["5K12EY016335"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jtos.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T03:39:53Z","timestamp":1542685193000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1340-6758","authenticated-orcid":false,"given":"Jia","family":"Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah S.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtos.2018.11.008_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ophtha.2011.01.041","article-title":"Horizons in therapy for corneal angiogenesis","volume":"118","author":"Maddula","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.jtos.2018.11.008_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"10.1016\/j.jtos.2018.11.008_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jtos.2018.06.004","article-title":"Current and emerging therapies for corneal neovascularization","volume":"16","author":"Roshandel","year":"2018","journal-title":"Ocul Surf"},{"issue":"4","key":"10.1016\/j.jtos.2018.11.008_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/ICO.0b013e3182542613","article-title":"Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis","volume":"32","author":"Papathanassiou","year":"2013","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2018.11.008_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ajo.2009.07.037","article-title":"Clinical benefits of the boston ocular surface prosthesis","volume":"149","author":"Stason","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2018.11.008_bib6","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/ICO.0b013e3182a73802","article-title":"Functional and visual improvement with prosthetic replacement of the ocular surface ecosystem scleral lenses for irregular corneas","volume":"32","author":"Lee","year":"2013","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2018.11.008_bib7","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajo.2014.07.016","article-title":"Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) scleral device compared to keratoplasty for the treatment of corneal ectasia","volume":"158","author":"DeLoss","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2018.11.008_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajo.2014.03.012","article-title":"Prosthetic replacement of the ocular surface ecosystem scleral lens therapy for patients with ocular symptoms of chronic Stevens-Johnson syndrome","volume":"158","author":"Heur","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2018.11.008_bib9","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.bbmt.2015.07.027","article-title":"Use of prosthetic replacement of the ocular surface ecosystem scleral lenses in patients with ocular chronic graft-versus-host disease","volume":"21","author":"Theophanous","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtos.2018.11.008_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ophtha.2014.08.015","article-title":"Prosthetic replacement of the ocular surface ecosystem as treatment for ocular surface disease in patients with a history of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"122","author":"Papakostas","year":"2015","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jtos.2018.11.008_bib11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bjophthalmol-2015-307483","article-title":"Prosthetic replacement of the ocular surface ecosystem: impact at 5 years","volume":"100","author":"Agranat","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2018.11.008_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/ICL.0000000000000265","article-title":"Prosthetic replacement of the ocular surface ecosystem scleral lens therapy for exposure keratopathy","volume":"43","author":"Chahal","year":"2017","journal-title":"Eye Contact Lens"},{"issue":"2","key":"10.1016\/j.jtos.2018.11.008_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jtos.2018.01.003","article-title":"Assessment of the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) scleral lens on visual acuity for corneal irregularity and ocular surface disease","volume":"16","author":"Parra","year":"2018","journal-title":"Ocul Surf"},{"issue":"6","key":"10.1016\/j.jtos.2018.11.008_bib14","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ajo.2013.06.006","article-title":"Treatment of persistent corneal epithelial defect with overnight wear of a prosthetic device for the ocular surface","volume":"156","author":"Lim","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2018.11.008_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/09273948.2014.894084","article-title":"Treatment of refractory persistent corneal epithelial defects: a standardized approach using continuous wear PROSE therapy","volume":"23","author":"Ciralsky","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.jtos.2018.11.008_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/08820530902802013","article-title":"The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab","volume":"24","author":"Lim","year":"2009","journal-title":"Semin Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2018.11.008_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1542-0124(11)70035-0","article-title":"Anti-vegf treatment of corneal neovascularization","volume":"9","author":"Keating","year":"2011","journal-title":"Ocul Surf"},{"issue":"2","key":"10.1016\/j.jtos.2018.11.008_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcrs.2004.01.014","article-title":"Visual acuity measurements","volume":"30","author":"Holladay","year":"2004","journal-title":"J Cataract Refract Surg"},{"issue":"4","key":"10.1016\/j.jtos.2018.11.008_bib19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jtos.2018.11.008_bib20","first-page":"14","article-title":"Current and upcoming therapies for corneal neovascularization","volume":"14","author":"Roshandel","year":"2018","journal-title":"Ocular surf"},{"issue":"6","key":"10.1016\/j.jtos.2018.11.008_bib21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2018.11.008_bib22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2018.11.008_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/ICO.0b013e31822480f9","article-title":"Anti-VEGF therapy with bevacizumab for anterior segment eye disease","volume":"31","author":"Hosseini","year":"2012","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.jtos.2018.11.008_bib24","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jtos.2018.11.008_bib25","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2018.11.008_bib26","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jfo.2010.07.007","article-title":"[Subconjunctival bevacizumab for corneal neovascularization]","volume":"33","author":"Gueudry","year":"2010","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jtos.2018.11.008_bib27","first-page":"1","article-title":"Corneal melt while using topical bevacizumab eye drops","author":"Galor","year":"2010","journal-title":"Ophthalmic Surg Laser Imag"},{"issue":"11","key":"10.1016\/j.jtos.2018.11.008_bib28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1097\/ICO.0b013e318245c044","article-title":"A case of recipient bed melt and wound dehiscence after penetrating keratoplasty and subconjunctival injection of bevacizumab","volume":"31","author":"Bhasin","year":"2012","journal-title":"Cornea"},{"issue":"11","key":"10.1016\/j.jtos.2018.11.008_bib29","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1097\/ICO.0b013e31825ec407","article-title":"Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab","volume":"32","author":"Chu","year":"2013","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2018.11.008_bib30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-3768.2011.02312.x","article-title":"The association between corneal neovascularization and visual acuity: a systematic review","volume":"91","author":"Bachmann","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2018.11.008_bib31","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.jtos.2018.11.008_bib32","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00417-011-1709-6","article-title":"Combination of vascular endothelial growth factor receptor\/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization","volume":"249","author":"Chaoran","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2018.11.008_bib33","article-title":"Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization","volume":"9","author":"Chen","year":"2014","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.jtos.2018.11.008_bib34","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012418302799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012418302799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T03:06:25Z","timestamp":1561950385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012418302799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1542012418302799"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2018.11.008","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}